
    
      The investigators propose to evaluate Molecular Breast Imaging in patients undergoing
      neoadjuvant therapy for breast cancer with the aims to document that 1) the change in uptake
      of 99mTc-sestamibi prior to initiation of neoadjuvant therapy, after 3-5 weeks of neoadjuvant
      therapy and at completion of neoadjuvant therapy prior to breast cancer surgery will be a
      reflection of the tumor response to neoadjuvant therapy.

      2) Tumor response at 3-5 weeks of neoadjuvant therapy is predictive of tumor response at
      completions of neoadjuvant therapy.

      3) Post-neoadjuvant tumor size as determined by MBI corresponds to size found at surgery.
    
  